Core B (Biorepository/Biostatistics). Core B will service Projects 1, 2, and 3 by providing clinically annotated human glioma tissue and serum samples and biostatistics support to the P01.
In Aim #1 (Biorepository), tissue and sera samples from newly diagnosed glioma patients, recurrent glioma patients an biopsy proven cases of radiation necrosis will be prospectively collected and designated for analysis. This will include the initial and longitudinal collection of sera and tumor tissue for a year following diagnosis. Overall, seven collaborating institutions have committed their support to this aim's biospecimen collections.Sample collection, annotation, storage, and analysis between participating sites will be coordinated using a web based sample tracking tool (GBCWEB) that has been created. In addition, the repository will receive and distribute biospecimen samples from non POl collaborating clinical trials that have already tested a specific molecularly targeted therapeutic (e.g. anti-EGFRvlll vaccination-Dr. Sampson, anti-PDGFR inhibition-Dr. Kesari;RTOG Iressa-Dr. Chakravarti). In collaborative fashion. Projects 2 and 3, Core B will test whether the molecular targets of these therapies can be monitored using microvesicle RNA technology. Finally, using the Biostatics and clinical expertise within the core, the Biorepository will generate appropriately powered patient sample sets for testing clinical hypotheses such as whether serum microvesicle RNA signatures of Temozolamide or bevacizamab chemotherapy be determined radiation necrosis versus recurrent glioma be distinguished using microvesicle RNA microarray analysis or whether serum microvesicle tumor specific mutation detection reflects treatment effect or prognosis.
In Aim #2 (Biostatistics), the Core will provide Biostatistical support (Dr. Messer) to all projects and Core C in validating sensitivity and specificity of assays and in appropriate study design.

Public Health Relevance

Glioma contributes the 2nd largest years of life lost to cancer, affecting a young population. It is highly lethal with low duration of survival after diagnosis. The ability to monitor and tailor therapeutics using a serum microvesicle based approach would be a significant advance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA069246-16
Application #
8475591
Study Section
Special Emphasis Panel (ZCA1-GRB-P)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
16
Fiscal Year
2013
Total Cost
$192,874
Indirect Cost
$45,327
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Ricklefs, Franz L; Alayo, Quazim; Krenzlin, Harald et al. (2018) Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv 4:eaar2766
Park, Jongmin; Im, Hyungsoon; Hong, Seonki et al. (2018) Analyses of Intravesicular Exosomal Proteins Using a Nano-Plasmonic System. ACS Photonics 5:487-494
Antoury, Layal; Hu, Ningyan; Balaj, Leonora et al. (2018) Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nat Commun 9:3906
Zhou, Shuang; Appleman, Vicky A; Rose, Christopher M et al. (2018) Chronic platelet-derived growth factor receptor signaling exerts control over initiation of protein translation in glioma. Life Sci Alliance 1:e201800029
Min, Jouha; Nothing, Maria; Coble, Ben et al. (2018) Integrated Biosensor for Rapid and Point-of-Care Sepsis Diagnosis. ACS Nano 12:3378-3384
Lee, Kyungheon; Fraser, Kyle; Ghaddar, Bassel et al. (2018) Multiplexed Profiling of Single Extracellular Vesicles. ACS Nano 12:494-503
ReƔtegui, Eduardo; van der Vos, Kristan E; Lai, Charles P et al. (2018) Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nat Commun 9:175
Speranza, Maria-Carmela; Passaro, Carmela; Ricklefs, Franz et al. (2018) Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol 20:225-235
Boussiotis, Vassiliki A; Charest, Alain (2018) Immunotherapies for malignant glioma. Oncogene 37:1121-1141
Sahin, Ayguen; Sanchez, Carlos; Bullain, Szofia et al. (2018) Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. PLoS One 13:e0199414

Showing the most recent 10 out of 223 publications